Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses.

Platelet-activating factor (PAF) is a lipid-derived mediator that has been implicated in the pathophysiology of airway inflammation in asthma. Its actions include chemotaxis and activation of inflammatory cells, particularly eosinophils. Inhaled PAF causes bronchoconstriction and increased airway responsiveness in human subjects. However, PAF antagonists have so far failed to show benefits in allergen challenge or in the treatment of chronic asthma. SR27417A is a novel PAF antagonist with increased potency compared with previously tested compounds. Twelve asthmatic subjects received treatment with either SR27417A or placebo for 1 wk in a double-blind crossover study. After treatment each subject underwent allergen challenge. Effects were assessed in terms of early and late asthmatic responses and allergen-induced effects on airway responsiveness. Baseline lung function and airway responsiveness were also examined. Treatment with SR27417A significantly attenuated the late asthmatic response (AUC LAR4-10h: 107 +/- 24 after placebo, 79 +/- 17 after SR27417A, p < 0.05; mean maximal percent fall in FEV1 LAR: 29 +/- 6% after placebo, 23.5 +/- 5.4% after SR27417A, p < 0.05). There were no effects on early asthmatic responses, allergen-induced airway responsiveness, or baseline lung measurements. SR27417A is the most potent PAF antagonist to date, and it has a modest inhibitory effect on the late asthmatic response. This suggests that PAF has a small role in allergic inflammation.

[1]  M. Yamakido,et al.  Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. , 1995, American journal of respiratory and critical care medicine.

[2]  K. Chung,et al.  Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. , 1995, American journal of respiratory and critical care medicine.

[3]  K. Chung,et al.  Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. , 1994, American journal of respiratory and critical care medicine.

[4]  P. Calverley,et al.  The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. , 1994, American journal of respiratory and critical care medicine.

[5]  P. O'Byrne,et al.  Effect of a platelet activating factor antagonist, WEB 2086, on allergen induced asthmatic responses. , 1993, Thorax.

[6]  J. Herbert,et al.  Effect of SR 27417 on the binding of [3H]PAF to rabbit and human platelets and human polymorphonuclear leukocytes. , 1993, Journal of lipid mediators.

[7]  K. P. Hui,et al.  Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen. , 1993, The American review of respiratory disease.

[8]  J. Herbert,et al.  Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. , 1991, The Journal of pharmacology and experimental therapeutics.

[9]  K. Hsieh.  Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. , 1991, Chest.

[10]  M. Chan-yeung,et al.  The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction. , 1991, The Journal of allergy and clinical immunology.

[11]  A. Zwinderman,et al.  The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. , 1991, The American review of respiratory disease.

[12]  P. Piper,et al.  Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man , 1990, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  Hwang Sb.  Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. , 1990 .

[14]  H. Heuer,et al.  Inhibitory effects of the new PAF acether antagonist WEB‐2086 on pharmacologic changes induced by PAF inhalation in human beings , 1990, Clinical pharmacology and therapeutics.

[15]  D. Hendrick,et al.  Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects. , 1990, The European respiratory journal.

[16]  S. Holgate,et al.  Inhaled PAF fails to induce airway hyperresponsiveness to methacholine in normal human subjects. , 1990, Journal of applied physiology.

[17]  W. Phillips,et al.  Intracellular platelet‐activating factor regulates eicosanoid generation in guinea‐pig resident peritoneal macrophages , 1989, British journal of pharmacology.

[18]  K. Chung,et al.  Stimulation of degranulation from human eosinophils by platelet-activating factor. , 1989, Journal of immunology.

[19]  K. Chung,et al.  Platelet-activating factor as a mediator of allergic disease. , 1988, The Journal of allergy and clinical immunology.

[20]  R. Patterson,et al.  The bronchoconstrictor properties of platelet-activating factor in humans. , 1987, The American review of respiratory disease.

[21]  P. Braquet,et al.  Effect of BN 52063, a specific PAF-acether antagonist, on bronchial provocation test to allergens in asthmatic patients. A preliminary study. , 1987, Prostaglandins.

[22]  F. Cuss,et al.  EFFECTS OF INHALED PLATELET ACTIVATING FACTOR ON PULMONARY FUNCTION AND BRONCHIAL RESPONSIVENESS IN MAN , 1986, The Lancet.

[23]  M. Parnham,et al.  Kadsurenone distinguishes between different platelet activating factor receptor subtypes on macrophages and polymorphonuclear leucocytes , 1986, British journal of pharmacology.

[24]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[25]  C. Page,et al.  Paf-acether: a mediator of inflammation and asthma , 1984 .